A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Low-dose Lurasidone in Acutely Psychotic Subjects With Schizophrenia.
Phase of Trial: Phase III
Latest Information Update: 08 Aug 2016
At a glance
- Drugs Lurasidone (Primary)
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- Sponsors Sunovion Pharmaceuticals
- 08 Aug 2016 Results published in a Sunovion Pharmaceuticals media release.
- 08 Aug 2016 Results published in the Journal of Clinical Psychiatry, according to a Sunovion Pharmaceuticals media release.
- 01 Sep 2015 Results presented at the 28th Annual Congress of the European College of Neuropsychopharmacology
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History